| __timestamp | Dr. Reddy's Laboratories Limited | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 12402000000 | 505679000 |
| Thursday, January 1, 2015 | 17449000000 | 487656000 |
| Friday, January 1, 2016 | 17834000000 | 660876000 |
| Sunday, January 1, 2017 | 19551000000 | 874278000 |
| Monday, January 1, 2018 | 18265000000 | 1431159000 |
| Tuesday, January 1, 2019 | 15607000000 | 2386000000 |
| Wednesday, January 1, 2020 | 15410000000 | 3137000000 |
| Friday, January 1, 2021 | 16541000000 | 4181000000 |
| Saturday, January 1, 2022 | 17482000000 | 5562000000 |
| Sunday, January 1, 2023 | 19381000000 | 7630000000 |
| Monday, January 1, 2024 | 22873000000 | 9748000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Dr. Reddy's Laboratories Limited and Genmab A/S have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Dr. Reddy's consistently increased its R&D budget, peaking in 2023 with a 55% rise from its 2014 levels. This commitment underscores their focus on expanding their drug pipeline and enhancing global competitiveness. Meanwhile, Genmab A/S, known for its pioneering work in antibody therapeutics, showed a remarkable 15-fold increase in R&D spending over the same period, reflecting its aggressive pursuit of cutting-edge biotechnological advancements. However, data for 2024 is missing for Genmab, leaving a gap in understanding their current strategy. These trends highlight the dynamic nature of R&D investments and their pivotal role in shaping the future of healthcare.
Comparing Innovation Spending: Bristol-Myers Squibb Company and Dr. Reddy's Laboratories Limited
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Genmab A/S
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Dr. Reddy's Laboratories Limited
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Research and Development Expenses Breakdown: Teva Pharmaceutical Industries Limited vs Dr. Reddy's Laboratories Limited
Research and Development: Comparing Key Metrics for Genmab A/S and Summit Therapeutics Inc.
Analyzing R&D Budgets: Genmab A/S vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Dr. Reddy's Laboratories Limited and Blueprint Medicines Corporation
Research and Development: Comparing Key Metrics for Dr. Reddy's Laboratories Limited and TG Therapeutics, Inc.
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Protagonist Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Dr. Reddy's Laboratories Limited and Soleno Therapeutics, Inc.
Dr. Reddy's Laboratories Limited vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending